Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Orexigen halts Contrave development for U.S., but the firm will appeal the division's "unprecedented" trial request through FDA's dispute resolution process.